{"id":7175,"date":"2025-05-29T10:35:12","date_gmt":"2025-05-29T07:35:12","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7175"},"modified":"2025-05-29T10:35:12","modified_gmt":"2025-05-29T07:35:12","slug":"a-new-era-in-reproductive-health-the-first-hormone-free-male-contraceptive-pill-and-its-implications-for-cardiovascular-safety-shows-early-promise","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/a-new-era-in-reproductive-health-the-first-hormone-free-male-contraceptive-pill-and-its-implications-for-cardiovascular-safety-shows-early-promise\/","title":{"rendered":"A New Era in Reproductive Health: The First Hormone-Free Male Contraceptive Pill and Its Implications for Cardiovascular Safety Shows Early Promise."},"content":{"rendered":"
A New Era in Reproductive Health: The First Hormone-Free Male Contraceptive Pill and Its Implications for Cardiovascular Safety Shows Early Promise.<\/div>\n
Source: Medscape.<\/div>\n
Date: May 20, 2025<\/div>\n
1. First of its kind:<\/span><\/div>\n
\u2022 YCT-529 is a nonhormonal male contraceptive pill in phase 2 clinical trials, developed by YourChoice Therapeutics (USA).<\/span><\/div>\n
2. Mechanism of action:<\/span><\/div>\n
\u2022 Targets retinoic acid receptor alpha, a protein essential for sperm production. Blocking it disrupts spermatogenesis without affecting testosterone.<\/span><\/div>\n
3. Animal study results:<\/span><\/div>\n
\u2022 In rats: infertility within 4 weeks.<\/span><\/div>\n
\u2022 In primates: significant sperm reduction within 2 weeks.<\/span><\/div>\n
\u2022 99% efficacy in preventing pregnancy in mice.<\/span><\/div>\n
4. Reversibility:<\/span><\/div>\n
\u2022 Fertility restored in 6 weeks (rats) and 2\u20133 months (primates) after stopping the drug \u2014 aligned with the human sperm regeneration cycle.<\/span><\/div>\n
5. No hormonal side effects:<\/span><\/div>\n
\u2022 Unlike testosterone-based pills, YCT-529 does not cause mood swings, erectile dysfunction, or loss of muscle mass.<\/span><\/div>\n
6. Safety profile:<\/span><\/div>\n
\u2022 No significant toxicity or lab abnormalities reported.<\/span><\/div>\n
\u2022 Testosterone levels remained stable throughout.<\/span><\/div>\n
7. Ongoing trials:<\/span><\/div>\n
\u2022 A phase 2 human trial in New Zealand is recruiting men (including those awaiting vasectomy) to test effectiveness and safety.<\/span><\/div>\n
8. Other methods in development:<\/span><\/div>\n
\u2022 Hormonal gel (norethisterone + testosterone)<\/span><\/div>\n
\u2022 EPPIN (nonhormonal protein blocker)<\/span><\/div>\n
\u2022 Vasalgel (reversible vas deferens plug, with some reversibility challenges)<\/span><\/div>\n
\u2022 Cottonseed-derived compounds (early stage)<\/span><\/div>\n
\u2022 Dimethandrolone undecanoate (hormonal pill)<\/span><\/div>\n
9. Key challenges:<\/span><\/div>\n
\u2022 Ensuring reversibility, safety, minimal side effects, and above all, male adherence and public acceptance.<\/span><\/div>\n
\u2022 Experts emphasize the need for awareness campaigns to shift contraceptive responsibility toward shared decision-making.<\/span><\/div>\n
10. Future outlook:<\/span><\/div>\n
<\/div>\n
\u2022 If successful in larger trials, YCT-529 may become the first viable male birth control pill \u2014 closing a long-standing gap in reproductive options for men.<\/span><\/div>\n
Read full article:<\/div>\n
https:\/\/www.medscape.com\/viewarticle\/first-hormone-free-male-pill-yct529-2025<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

A New Era in Reproductive Health: The First Hormone-Free Male Contraceptive Pill and Its Implications for Cardiovascular Safety Shows Early Promise. Source: Medscape. Date: May 20, 2025 1. First of its kind: \u2022 YCT-529 is a nonhormonal male contraceptive pill in phase 2 clinical trials, developed by YourChoice Therapeutics (USA). 2. Mechanism of action: \u2022 […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7175","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7175"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7175\/revisions"}],"predecessor-version":[{"id":7176,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7175\/revisions\/7176"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}